1. Home
  2. CMI vs ARGX Comparison

CMI vs ARGX Comparison

Compare CMI & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMI
  • ARGX
  • Stock Information
  • Founded
  • CMI 1919
  • ARGX 2008
  • Country
  • CMI United States
  • ARGX Netherlands
  • Employees
  • CMI N/A
  • ARGX N/A
  • Industry
  • CMI Industrial Machinery/Components
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CMI Industrials
  • ARGX Health Care
  • Exchange
  • CMI Nasdaq
  • ARGX Nasdaq
  • Market Cap
  • CMI 39.3B
  • ARGX 33.0B
  • IPO Year
  • CMI N/A
  • ARGX 2017
  • Fundamental
  • Price
  • CMI $355.95
  • ARGX $673.80
  • Analyst Decision
  • CMI Buy
  • ARGX Strong Buy
  • Analyst Count
  • CMI 11
  • ARGX 18
  • Target Price
  • CMI $363.00
  • ARGX $736.94
  • AVG Volume (30 Days)
  • CMI 929.1K
  • ARGX 440.8K
  • Earning Date
  • CMI 08-05-2025
  • ARGX 07-31-2025
  • Dividend Yield
  • CMI 2.25%
  • ARGX N/A
  • EPS Growth
  • CMI 47.91
  • ARGX N/A
  • EPS
  • CMI 20.10
  • ARGX 18.75
  • Revenue
  • CMI $33,873,000,000.00
  • ARGX $3,120,821,000.00
  • Revenue This Year
  • CMI N/A
  • ARGX $64.75
  • Revenue Next Year
  • CMI $5.59
  • ARGX $29.81
  • P/E Ratio
  • CMI $17.70
  • ARGX $32.24
  • Revenue Growth
  • CMI N/A
  • ARGX 88.04
  • 52 Week Low
  • CMI $260.02
  • ARGX $475.65
  • 52 Week High
  • CMI $387.90
  • ARGX $689.13
  • Technical
  • Relative Strength Index (RSI)
  • CMI 57.05
  • ARGX 82.36
  • Support Level
  • CMI $362.42
  • ARGX $590.78
  • Resistance Level
  • CMI $370.51
  • ARGX $689.13
  • Average True Range (ATR)
  • CMI 7.13
  • ARGX 12.75
  • MACD
  • CMI 0.18
  • ARGX 11.01
  • Stochastic Oscillator
  • CMI 51.10
  • ARGX 88.61

About CMI Cummins Inc.

Cummins is the top manufacturer of diesel engines used in commercial trucks, off-highway machinery, and railroad locomotives, in addition to standby and prime power generators. The company also sells powertrain components, which include transmissions, turbochargers, aftertreatment systems, and fuel systems. Cummins is in the unique position of competing with its primary customers, heavy-duty truck manufacturers, who make and aggressively market their own engines. Despite robust competition across all its segments and increasing government regulation of carbon emissions, Cummins has maintained its leadership position in the industry.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: